Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States.
Not yet scored
31.01 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 7 days ago
Screened 2026-10-23 · the tape above runs as of 10:08 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price31.01 USD at the 23 Oct 2026 close
Ethical screenNot yet scored
OptionsOpen interest leans slightly to calls (put/call 0.77)
Last reviewed23 Oct 2026 (7 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 31.01 against the desk's fair-value range, base estimate 55.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.77, read 2026-10-29
Ethical screen not yet scored
Price31.01 USD
Fair value55.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-28Read Accumulation31.95-2.9% to today Markup gives way to Accumulation after a 43% rise in 4 weeks
2026-10-02Read Markup22.39+38.5% to today ✓Markdown gives way to Markup after a 22% slide in 4 weeks
2026-09-04Read Markdown28.60+8.4% to today Accumulation gives way to Markdown after a 19% rise in 9 weeks
2026-07-02Read Accumulation24.05+28.9% to today ✓First review on file: Accumulation
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Maze Therapeutics, Inc. holds its Accumulation at $31.01. The statistical read favours the sellers, held for 21 days.
As held on the ledger · 2026-10-23
Phase
Accumulation
Quantitative state
The statistical read favours the sellers, held for 21 days
Price at the screen
$31.01
Valuation
N/A trailing · -10.02 forward price to earnings
Values screen
Not scored· score 70.0
The Workings
Five Screens, Shown in Full
This security has not been fully scored against the values screen yet.
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
5.87%
Below 33%
Interest-bearing debt is just 5.9% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
4.56%
Below 33%
Cash held in interest-bearing accounts and securities is 4.6% of assets, under the one-third limit.
Pass
Receivables
47.65%
Below 49%
Money owed to the company is 47.7% of assets, under the 49% limit.
Pass
Revenue purity
2.78%
Below 5%
Only 2.8% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
The Read, in Plain English
Maze Therapeutics, clears the business-activity screen and the figures we can measure look clean, but its income-purity figure is still pending, so the verdict is not final yet.
Read as at 2026-10-29. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 77.4% margin of safety to the base estimate.
Third-party analyst targets: 13 covering, consensus Strong Buy. The average target sits +77% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Early kidney drug bets face binary odds
Picture a lab team racing to turn one molecule into a working pill for rare kidney disease before the cash runs out. Maze Therapeutics sits at that exact point, a clinical stage group with no sales, zero profit margin and a return on equity at minus 39 percent. The market prices the shares at roughly half our internal fair value, yet the opportunity rating stays at none because the business has yet to clear the first real proof point.
Forward earnings sit in negative territory and the moat remains unknown, which leaves the entire story resting on clinical data that may still fail. Eleven analysts call it a strong buy with a median target matching our number, but those forecasts assume success that has not been delivered. The ethical screen clears, yet that alone does not create an investable edge when the company burns cash to reach the next trial readout.
Risk sits in the usual biotech pattern of binary outcomes, dilution and long waits for any revenue. A single failed study can erase most of the apparent discount in weeks. Analysis, not advice.
The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
MAZE trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-30Accumulation$31.01+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 83%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (11 analysts) rates it strong buy, with a mean price target of $63. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-29Accumulation$31.01-2.9%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 2.9% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 83%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (11 analysts) rates it strong buy, with a mean price target of $63. Insiders have been net sellers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 19.8% since our last review. Ethical screening: not fully scored yet. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are up 83%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (11 analysts) rates it strong buy, with a mean price target of $63. Insiders have been net sellers over the past quarter.
2026-10-21Markup$26.66-1.7%Entry 8
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are up 83%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (11 analysts) rates it strong buy, with a mean price target of $63. Insiders have been net sellers over the past quarter.
2026-10-14Markup$27.11+21.1%Entry 7
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 21.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 83%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (11 analysts) rates it strong buy, with a mean price target of $63. Insiders have been net sellers over the past quarter.
2026-10-02Markup · changed$22.39-21.7%Entry 6
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 21.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 83%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (11 analysts) rates it strong buy, with a mean price target of $63. Insiders have been net sellers over the past quarter.
2026-09-04Markdown · changed$28.60+1.7%Entry 5
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 1.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 83%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (11 analysts) rates it strong buy, with a mean price target of $63. Insiders have been net sellers over the past quarter.
2026-08-05Accumulation$28.12+16.9%Entry 4
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 16.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 83%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (11 analysts) rates it strong buy, with a mean price target of $63.
2026-07-18Accumulation$24.05+0.0%Entry 3
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C. Technically it is momentum reading neutral. Over the past year the shares are up 83%. Our forward projection puts the odds of a 10% gain over the next month near 37%. The street (11 analysts) rates it strong buy, with a mean price target of $63.
2026-07-03Accumulation$24.05+0.0%Entry 2
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
